Does residual microscopic disease after chemoradiotherapy for locally advanced rectal cancer translate into a good clinical outcome?

2017 ◽  
Vol 19 (3) ◽  
pp. 237-242
Author(s):  
R. Geva ◽  
H. Davidovics ◽  
S. Soyfer ◽  
S. Pelles-Avraham ◽  
J. M. Klausner ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Clinical Outcome ◽  
Locally Advanced ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer ◽  
Good Clinical Outcome ◽  
Residual Microscopic Disease

Clinical outcome in patients who did not accept complementary surgery after neoadjuvant chemoradiotherapy (QT-RT) in locally advanced rectal cancer (LARC).

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e15144-e15144
Author(s):  
German Caderillo-Ruiz ◽  
Dr. Consuelo Diaz ◽  
Horacio Noe López-Basave ◽  
MaryTere Herrera ◽  
Erika Ruiz Garcia ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Clinical Outcome ◽  
Locally Advanced ◽  
Neoadjuvant Chemoradiotherapy ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer

scholarly journals PO-0694: Coexpression of VEGFR and Ki67 on clinical outcome in patients with locally advanced rectal cancer

2013 ◽  
Vol 106 ◽  
pp. S266
Author(s):  
C. Solé ◽  
F.A. Calvo ◽  
E. Alvarez ◽  
I. Peligros ◽  
M. Gomez-Espi ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Clinical Outcome ◽  
Locally Advanced ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer

scholarly journals 8-Oxoguanine DNA Glycosylase (OGG1) Cys326 Variant: Increased Risk for Worse Outcome of Patients with Locally Advanced Rectal Cancer after Multimodal Therapy

Cancers ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 2805
Author(s):  
Martin Leu ◽  
Theresa Riebeling ◽  
Leif Hendrik Dröge ◽  
Laura Hubert ◽  
Manuel Guhlich ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Clinical Outcome ◽  
Cox Regression ◽  
Locally Advanced ◽  
Multivariable Analysis ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer ◽  
Rank Test ◽  
Neoadjuvant Radiochemotherapy ◽  
Increased Risk

Despite excellent loco-regional control by multimodal treatment of locally advanced rectal cancer, a substantial portion of patients succumb to this disease. As many treatment effects are mediated via reactive oxygen species (ROS), we evaluated the effect of single nucleotide polymorphisms (SNPs) in ROS-related genes on clinical outcome. Based on the literature, eight SNPs in seven ROS-related genes were assayed. Eligible patients (n = 287) diagnosed with UICC stage II/III rectal cancer were treated multimodally starting with neoadjuvant radiochemotherapy (N-RCT) according to the clinical trial protocols of CAO/ARO/AIO-94, CAO/ARO/AIO-04, TransValid-A, and TransValid-B. The median follow-up was 64.4 months. The Ser326Cys polymorphism in the human OGG1 gene affected clinical outcome, in particular cancer-specific survival (CSS). This effect was comparable in extent to the ypN status, an already established strong prognosticator for patient outcome. Homozygous and heterozygous carriers of the Cys326 variant (n = 105) encountered a significantly worse CSS (p = 0.0004 according to the log-rank test, p = 0.01 upon multiple testing adjustment). Cox regression elicited a hazard ratio for CSS of 3.64 (95% confidence interval 1.70–7.78) for patients harboring the Cys326 allele. In a multivariable analysis, the effect of Cys326 on CSS was preserved. We propose the genetic polymorphism Ser326Cys as a promising biomarker for outcome in rectal cancer.

Sign in / Sign up

Export Citation Format

Share Document